US Patent

US8334270 — Nucleoside phosphoramidate prodrugs

Method of Use · Assigned to Gilead Pharmasset LLC · Expires 2028-03-21 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects phosphoramidate prodrugs of nucleoside derivatives for treating viral infections in mammals.

USPTO Abstract

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-2040 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —
U-1470 —

Patent Metadata

Patent number
US8334270
Jurisdiction
US
Classification
Method of Use
Expires
2028-03-21
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Gilead Pharmasset LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.